Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Leslie L. Muldoon(Oregon Health & Science University), Edward A. Neuwelt(Oregon Health & Science University), Walter A. Hall(SUNY Upstate Medical University), Conrad E. Johanson(Texas Tech University), David M. Peereboom(Texas Tech University), Kullervo Hynynen(University of Toronto), Peter D. Senter(Seagen (United States)), Quentin R. Smith(Texas Tech University), Tali Siegal(Rabin Medical Center), Kristoph Jahnke(Texas Tech University), Carole Soussain(Institut Curie)
Cited by 414
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772